Form 4: Lyell Immunopharma VP Executes Tax-Related Stock Sale

Veronica Sanchez, VP and Corporate Controller of Lyell Immunopharma, sold 217 shares to cover tax obligations related to vested restricted stock units.

Summary

• Veronica Sanchez, VP, Corporate Controller at Lyell Immunopharma, Inc. (LYEL), sold 217 shares of common stock.
• The transaction occurred on May 11, 2026.
• The shares were sold at a weighted average price of $18.91 per share, with a price range between $18.91 and $19.30.
• Following the transaction, the reporting person retains 15,420 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax purposes rather than a discretionary divestment.

Positives

• The sale was non-discretionary, executed solely to satisfy tax withholding obligations resulting from the vesting of restricted stock units.

Negatives

• The transaction represents a reduction in the insider's direct equity stake in the company.

Risks

• General market volatility affecting the share price of biotechnology companies.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Management Comments

• The sale was conducted automatically to cover tax withholding obligations from the settlement of vested restricted stock units.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for corporate executives in the biotechnology sector to manage tax liabilities associated with equity compensation vesting.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation and tax management practices observed across the mid-cap biotechnology industry.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Insider Trading, Form 4, Biotechnology, Tax Withholding